These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31836287)

  • 1. Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis.
    Yamada T; Ooi Y; Oda K; Shibata Y; Kawanishi F; Suzuki K; Nishihara M; Nakano T; Yoshida M; Uchida T; Katsumata T; Ukimura A
    J Infect Chemother; 2020 Apr; 26(4):379-384. PubMed ID: 31836287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation.
    Ando M; Nishioka H; Nakasako S; Kuramoto E; Ikemura M; Kamei H; Sono Y; Sugioka N; Fukushima S; Hashida T
    J Clin Pharm Ther; 2020 Apr; 45(2):290-297. PubMed ID: 31696963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.
    Bhavnani SM; Rubino CM; Ambrose PG; Drusano GL
    Clin Infect Dis; 2010 Jun; 50(12):1568-74. PubMed ID: 20462352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.
    Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between pharmacokinetic/pharmacodynamic indices and clinical outcomes in Japanese patients with skin and soft tissue infections treated with daptomycin: analysis of a phase III study.
    Takesue Y; Mikamo H; Kusachi S; Watanabe S; Takahashi K; Yoshinari T; Ishii M; Aikawa N
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):77-81. PubMed ID: 26072149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of daptomycin in a clinical setting.
    Tsukada H; Tsuji Y; Yamashina T; Tsuruta M; Hiraki Y; Tsuruyama M; Ogami C; Kawasuji H; Sakamaki I; Yamamoto Y
    J Infect Chemother; 2020 Feb; 26(2):230-235. PubMed ID: 31735632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.
    Lefèvre S; Saleh M; Marcellin L; Subilia A; Bourcier T; Prévost G; Jehl F
    Antimicrob Agents Chemother; 2012 May; 56(5):2485-92. PubMed ID: 22371888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations about the Use of a Loading Dose of Daptomycin in a Neutropenic Murine Thigh Infection Model with Methicillin-Resistant Staphylococcus aureus Infection.
    Kato H; Hagihara M; Murakami E; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Uno B; Mikamo H
    Chemotherapy; 2018; 63(1):13-19. PubMed ID: 29130946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy.
    De Gregori S; De Silvestri A; Molinaro MD; Monzillo V; Biscarini S; Colaneri M; Gallazzi I; Bartoli A; Bruno R; Seminari E
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):547-554. PubMed ID: 34231117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis.
    Butterfield JM; Mueller BA; Patel N; Cardone KE; Grabe DW; Salama NN; Lodise TP
    Antimicrob Agents Chemother; 2013 Feb; 57(2):864-72. PubMed ID: 23208714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Falcone M; Russo A; Venditti M; Novelli A; Pai MP
    Clin Infect Dis; 2013 Dec; 57(11):1568-76. PubMed ID: 24046298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods.
    Imai S; Kashiwagi H; Sato Y; Miyai T; Sugawara M; Takekuma Y
    Br J Clin Pharmacol; 2022 Mar; 88(3):1211-1222. PubMed ID: 34436795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.
    Cardone KE; Lodise TP; Patel N; Hoy CD; Meola S; Manley HJ; Drusano GL; Grabe DW
    Clin J Am Soc Nephrol; 2011 May; 6(5):1081-8. PubMed ID: 21393490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults.
    Butterfield-Cowper JM; Lodise TP; Pai MP
    Pharmacotherapy; 2018 Sep; 38(9):981-985. PubMed ID: 29906315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus.
    Soon RL; Turner SJ; Forrest A; Tsuji BT; Brown J
    Int J Antimicrob Agents; 2013 Jul; 42(1):53-8. PubMed ID: 23684388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
    Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
    Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients.
    Urakami T; Hamada Y; Oka Y; Okinaka T; Yamakuchi H; Magarifuchi H; Aoki Y
    J Infect Chemother; 2019 Jun; 25(6):437-443. PubMed ID: 30782427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Risk Factors for Daptomycin-Associated Creatine Phosphokinase Elevation and Development of a Risk Prediction Model for Incidence Probability.
    Samura M; Hirose N; Kurata T; Takada K; Nagumo F; Koshioka S; Ishii J; Uchida M; Inoue J; Enoki Y; Taguchi K; Higashita R; Kunika N; Tanikawa K; Matsumoto K
    Open Forum Infect Dis; 2021 Dec; 8(12):ofab568. PubMed ID: 34888403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing strategy to allow continued therapy with daptomycin after asymptomatic increases in creatine kinase levels.
    Burdette SD; Oleson F; McDaneld PM; Benziger D; Patel HN
    Am J Health Syst Pharm; 2014 Jul; 71(13):1101-7. PubMed ID: 24939500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.